Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59404

Grau, Thomas; Selchow, Petra; Tigges, Marcel; Burri, Reto; Gitzinger, Marc; Böttger, Erik C; Fussenegger, Martin; Sander, Peter (2012). Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 56(2):1142-1145.

[img]Published Version
PDF - Registered users only
763kB
View at publisher

Abstract

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.

Citations

10 citations in Web of Science®
11 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 03 Apr 2012
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Institute of Medical Microbiology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:2012
Deposited On:03 Apr 2012 08:57
Last Modified:05 Apr 2016 15:38
Publisher:American Society for Microbiology (ASM)
ISSN:0066-4804
Publisher DOI:10.1128/AAC.05649-11
PubMed ID:22106218

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page